Johnson & Johnson's ($JNJ) new Prezista formulation, a once-daily 800 mg pill, won approval from European regulators. The FDA gave its blessing to the new HIV drug in November. The original Prezista is set to lose exclusivity in 2017. Report
| Tuesday, January 27 | 2 p.m. ET / 11 a.m. PT | Sponsored by: Veeva
As the life sciences industry evolves, commercial leaders are demanding more innovative and effective customer engagement, but traditional processes limited by legacy technology are holding them back. There is a better way that puts control back in the hands of commercial leaders and eliminates the barriers to coordinated customer engagement. Reserve Your Spot Today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!